These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32606594)

  • 21. Brief report on Ziprasidone.
    Firoz AH; Rahman AH; Chowdhury WA; Mamun AA
    Mymensingh Med J; 2002 Jul; 11(2):129-32. PubMed ID: 12395687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study.
    Wessels AM; Bies RR; Pollock BG; Schneider LS; Lieberman JA; Stroup S; Li CH; Coley K; Kirshner MM; Marder SR
    J Clin Pharmacol; 2011 Nov; 51(11):1587-91. PubMed ID: 21209243
    [No Abstract]   [Full Text] [Related]  

  • 23. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ziprasidone: a new atypical antipsychotic.
    Keck PE; McElroy SL; Arnold LM
    Expert Opin Pharmacother; 2001 Jun; 2(6):1033-42. PubMed ID: 11585006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder.
    Mandrioli R; Protti M; Mercolini L
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):149-74. PubMed ID: 25483358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
    Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ziprasidone for schizophrenia and severe mental illness.
    Bagnall A; Lewis RA; Leitner ML
    Cochrane Database Syst Rev; 2000; (4):CD001945. PubMed ID: 11034737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial.
    Mautone A; Scarone S;
    Pharmacopsychiatry; 2011 Jul; 44(5):173-8. PubMed ID: 21751127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
    Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
    Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.
    Ou JJ; Xu Y; Chen HH; Fan X; Gao K; Wang J; Guo XF; Wu RR; Zhao JP
    Psychopharmacology (Berl); 2013 Feb; 225(3):627-35. PubMed ID: 22926006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using oral ziprasidone effectively: the food effect and dose-response.
    Citrome L
    Adv Ther; 2009 Aug; 26(8):739-48. PubMed ID: 19669631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study.
    Addington DE; Labelle A; Kulkarni J; Johnson G; Loebel A; Mandel FS
    Can J Psychiatry; 2009 Jan; 54(1):46-54. PubMed ID: 19175979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ziprasidone for schizophrenia and severe mental illness.
    Bagnall A; Lewis RA; Leitner ML; Kleijnen J
    Cochrane Database Syst Rev; 2000; (2):CD001945. PubMed ID: 10796670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial.
    Bogers JPAM; Schulte PFJ; Broekman TG; Moleman P; de Haan L
    Eur Neuropsychopharmacol; 2018 Sep; 28(9):1024-1034. PubMed ID: 30025751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine Dā‚‚/ā‚ƒ occupancy of ziprasidone across a day: a within-subject PET study.
    Suzuki T; Graff-Guerrero A; Uchida H; Remington G; Caravaggio F; Borlido C; Pollock B; Mulsant B; Deluca V; Ismail Z; Mamo D
    Psychopharmacology (Berl); 2013 Jul; 228(1):43-51. PubMed ID: 23417515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.
    Keck P; Buffenstein A; Ferguson J; Feighner J; Jaffe W; Harrigan EP; Morrissey MR
    Psychopharmacology (Berl); 1998 Nov; 140(2):173-84. PubMed ID: 9860108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From clinical research to clinical practice: a 4-year review of ziprasidone.
    Nemeroff CB; Lieberman JA; Weiden PJ; Harvey PD; Newcomer JW; Schatzberg AF; Kilts CD; Daniel DG
    CNS Spectr; 2005 Nov; 10(11 Suppl 17):1-20. PubMed ID: 16381088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.